GH Research PLC (NasdaqGM: GHRS)
Health Care · Pharmaceuticals · IE
$21.06
-8.20% today · +75.7% 1Y
GH Research PLC (NasdaqGM: GHRS) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.57B and employs 73 people.
Over the last twelve months the share price has gained 75.7%, trading between 12.04 and 31.44.
Tweenvest scores GH Research PLC across four factors: quality 42/100, value 77/100. Its strongest factor is value.
GHRS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.57B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.99
- Dividend yield
- —
- Beta (5Y)
- 1.33
- 52-week high
- $31.44
- 52-week low
- $12.04
- Avg volume (3M)
- —
- Shares outstanding
- 68.64M
- Employees
- 73
- Next earnings
- —
About GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
- ISIN
- IE000GID8VI0
- Founded
- 2018
- Listed since
- Jun 25, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Ocular Therapeutix, Inc.NasdaqGM: OCUL | $1.59B | $7.23 | -1.50% |
| Consun Pharmaceutical Group LimitedSEHK: 1681 | $1.59B | HK$14.85 | -0.54% |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.SZSE: 300357 | $1.59B | CN¥20.33 | +1.90% |
| Sopharma ADBUL: SFA | $1.58B | €2.63 | +5.20% |
| Square Pharmaceuticals PLC.DSE: SQURPHARMA | $1.57B | Tk218.30 | +0.32% |
| CSPC Hunan Jingfeng Pharmaceutical Co., Ltd.SZSE: 000908 | $1.57B | CN¥5.99 | -0.99% |
| Eton Pharmaceuticals, Inc.NasdaqGM: ETON | $1.57B | $54.88 | +0.20% |
| AstraZeneca Pharma India LimitedBSE: 506820 | $1.57B | Rs6,030.45 | -7.48% |
Figures last refreshed Oct 4, 2026.